ClinicalTrials.gg
CompletedNCT04294654MEMORYUpdated Aug 8, 2022

Vortioxetine in Patients With Depression and Early Dementia

A Phase 4 interventional study of Vortioxetine in Major Depressive Disorder and Dementia, sponsored by H. Lundbeck A/S. Completed at 24 sites in 6 countries. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-08-08.

Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
43rd of 54
82 · median 413
Started
2020
with 2 others
Phase 4
13 of 54
none open now
Registered
49th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 43rd largest by enrollment, is one of 3 that started in 2020, is one of 13 in phase 4, and was the 49th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression and early dementia

03

Conditions studied

  • Major Depressive Disorder
  • Dementia
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has a primary diagnosis of recurrent Major Depressive Disorder (MDD) with onset before age of 55, diagnosed according to ®
  • The current major depressive episode (MDE) must be confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient has had the current MDE for \<6 months.
  • The patient has a Montgomery and Åsberg Depression Rating Scale (MADRS) total score ≥26 at the Baseline Visit.
  • The diagnosis of onset of dementia has occurred at least 6 months prior to screening and after already being diagnosed with MDD. The diagnosis of dementia must be documented in patient's medical records. When deemed necessary per investigator judgement of patient clinical status and early dementia, the patient must be accompanied by a caregiver to study visits.
  • Patients with dementia associated with vitamin B12 or folate deficiency should not be enrolled.
  • Patients with or without treatment for dementia can be enrolled. For patients on treatment for dementia, there must be no change in treatment during the study and patients must be on stable dose for at least 3 months prior to the Screening Visit.
  • The patient has (MMSE) total score 20-24, inclusive.

Exclusion criteria

Exclusion Criteria:

-The patient has any current psychiatric disorder or Axis I disorder (® criteria), established as the primary diagnosis, other than MDD, as assessed using the Mini International Neuropsychiatric Interview (MINI) or another diagnostic interview.

Other in- and exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    5 - 20 mg/day tablets

    Drug: Vortioxetine

Interventions

  • Vortioxetine 5, 10 and 20 mg/day, tablets, orally Patients will receive 5 mg vortioxetine once daily for one week. At visit 3, the dose will be increased to 10 mg/day for all patients. Thereafter the dose may be adjusted to 5, 10 or 20 mg/day.

06

What researchers measure

Primary outcomes

  1. Change in Montgomery and Åsberg Depression Rating Scale (MADRS) total score

    The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.

    Time frame: from baseline to Week 12

Secondary outcomes

  1. Change in Digit-Symbol Substitution Test (DSST) Substitution Test (DSST) score

    Digit Symbol Substitution Test (DSST) is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted, and the total score ranges from 0 (less than normal functioning) to 133 (greater than normal functioning)."

    Time frame: from baseline to Week 12

  2. Change in Rey Auditory Verbal Learning Test (RAVLT) score

    Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded.

    Time frame: from baseline to Week 12

  3. Change in Instrumental Activities of Daily Living (IADL) score

    The Instrumental Activities of Daily Living (IADL) measures an individual's ability to carry out tasks that are important for daily living and capture functional changes. Scores for each question range from 0 (no assistance needed) to 2 (full assistance needed), and are assessed by informant interview. The scores for IADL (0-14) is the outcome, with higher scores indicating lesser ability to carry out daily living tasks

    Time frame: from baseline to Week 12

  4. Change in Clinical Global Impression - Severity (CGI-S) score

    The Clinical Global Impression severity of illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

    Time frame: from baseline to Week 12

  5. Clinical Global Impression - Improvement (CGI-I) score

    The Clinical Global Impression - global improvement CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: at Week 12

  6. Response defined by decrease in MADRS total score

    Response is defined as a 50% decrease from baseline in MADRS total score

    Time frame: At Week 12

  7. Remission defined by MADRS score

    Remission is defined as MADRS ≤10

    Time frame: at Week 12

  8. Change in Bath Assessment of Subjective Quality of Life in Dementia (BASQID) score

    The BASQID30 is a clinician rating scale designed to assess subjective quality of life (QoL) in patients with dementia. The BASQID contains 14 core questions, which are scored from 0 to 4, with 4 indicating a better QoL.

    Time frame: from baseline to Week 12

07

Study locations

24 sites
  • Marienthali Kliinik
    Tallinn, 11315, Estonia
  • Cabinet du Docteur Karim Boutayeb
    Viersat, 23170, France
  • Centre de Recherche-Hopital Geriatrique de Charpennes
    Villeurbanne, 69100, France
  • Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
    Brescia, Province Of Brescia 25123, Italy
  • Azienda Ospedaliera di Perugia - Policlinico Monteluce
    Perugia, Umbria 06122, Italy
  • Fondazione Universitaria G.D'Annunzio Ce.S.I. Centro Ricerca (Centro Scienze del l'Invecchiamento...
    Chieti, 66100, Italy
  • Fondazione Santa Lucia IRCCS
    Rome, 00179, Italy
  • Inje University Ilsan Paik Hospital
    Goyang-si, Gyeonggi-do 10380, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju-si, 61469, Korea, Republic of
  • Nowon Eulji Medical Center, Eulji University
    Seoul, 01830, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Clinical Research Center Spolka z ograniczona odpowiedzialnoscia Medic-R Spolka Komandytowa
    Poznan, Wielkopolskie 60-848, Poland
  • MlynowaMed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk
    Bialystok, 15-404, Poland
  • NZOZ Dom Sue Ryder - Pallmed Sp. z o.o.
    Bydgoszcz, 85-023, Poland
  • CareClinic
    Katowice, 40-568, Poland
  • Centrum Zdrowia Psychicznego Biomed - Jan Latala
    Kielce, 25-411, Poland
  • Niepubliczny Zaklad Opieki Psychiatrycznej Mentis
    Leszno, 64-100, Poland
  • Centrum Medyczne Luxmed Sp.Z O.O.
    Lublin, 20-109, Poland
  • Nzoz Syntonia
    Pruszcz Gdanski, 83-000, Poland
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • University Clinical Hospital of Valladolid
    Valladolid, 47010, Spain
  • Hospital Río Hortega
    Valladolid, 47012, Spain
  • Centro de Saude de Lavadores
    Vigo, 36214, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Jul 2022, 28 months.

Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2020
First posted
Mar 4, 2020
StartActual
Feb 28, 2020
Primary completionActual
Jul 6, 2022
CompletionActual
Jul 20, 2022
Last update
Aug 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04294654
Lead sponsor
H. Lundbeck A/S
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Mar 4, 2020
Start date
Feb 28, 2020
Primary completion
Jul 6, 2022
Completion
Jul 20, 2022
Last update
Aug 8, 2022

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion